Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
Zai Lab Limited reported Q3 2025 results showing higher sales and a narrower loss. Total revenues were $116.1 million (up 14% year over year), driven by net product revenue of $115.4 million. The company posted a net loss of $36.0 million, improving from a $41.7 million loss a year ago, with basic and diluted loss per share of $0.03.
Growth was led by NUZYRA $15.4M (+54% YoY), OPTUNE $12.7M (+64% YoY), and contributions from XACDURO $6.4M and AUGTYRO $1.7M, while ZEJULA $42.4M declined 12% amid class competition. R&D expenses fell to $47.9M (down 27%), reflecting lower licensing fees, and SG&A was $70.1M. Cash and cash equivalents were $717.2 million as of September 30, 2025; short‑term debt was $203.0 million. Shares outstanding were 1,105,937,600 as of October 31, 2025.
Zai Lab Limited filed a Form 8-K stating it furnished a press release announcing its third-quarter 2025 financial results. The press release is included as Exhibit 99.1 and is provided under Item 2.02 (Results of Operations and Financial Condition). The information is furnished and not deemed filed under the Exchange Act. The company’s ADSs, each representing 10 ordinary shares, trade on Nasdaq under ZLAB, with ordinary shares listed in Hong Kong under 9688.
Zai Lab (ZLAB) disclosed insider activity by its Chief Financial Officer. On 10/31/2025, 500 American Depositary Shares (ADS) were acquired upon the vesting of restricted share units (RSUs). On 11/03/2025, 240 ADS were sold at $26.831 per ADS to cover taxes associated with the vesting. Following these transactions, the officer directly owned 17,444 ADS.
Each ADS represents ten Ordinary Shares. Each RSU represents a contingent right to receive one ADS, with the grant vesting in equal annual installments over four years beginning on 11/01/2022.
Zai Lab Limited entered into a maximum amount guarantee and established a revolving credit facility to support working capital in mainland China. The company will guarantee working capital loans of up to RMB300 million (approximately $42.1 million) from Industrial Bank Co., Ltd., Shanghai Gubei Branch, to its wholly owned subsidiary, Zai Lab (Shanghai) Co., Ltd.
The RMB300 million revolving credit facility is available until May 5, 2026. Each working capital loan is expected to have a one‑year term, with specific amounts, terms, and interest rates set in loan‑level documents. The credit line includes customary representations, warranties, and covenants, including a requirement to obtain prior written consent from the lender for transactions that could adversely impact debt repayment ability, such as mergers, spin-offs, equity transfers, external investments, or substantial debt increases.
As of this report, Zai Lab Shanghai has not entered into any working capital loans under the facility.
Chen Yajing, Chief Financial Officer of Zai Lab Ltd (ZLAB), reported the vesting and partial automatic sale of restricted share units. On 10/01/2025 she had 920 ADS vest (each ADS represents ten ordinary shares), increasing her beneficial ownership to 17,640 ADS. On 10/02/2025 456 ADS were sold at $34.247 per ADS to cover taxes, leaving 17,184 ADS beneficially owned. The RSUs vest in equal annual installments over five years beginning 10/01/2022, and vested ADS are delivered following vesting.
Zai Lab Ltd (ZLAB) filed a Form 144 reporting a proposed sale of 456 American Depositary Shares (ADS) with an aggregate market value of $15,616.6810/02/2025 through Fidelity Brokerage Services on NASDAQ. The ADS were acquired on 10/01/2025 via restricted stock vesting and were paid as compensation. The filer also disclosed two prior sales in the last three months: 4,096 ADS sold on 08/08/2025 for $139,304.96 and 1,438 ADS sold on 08/15/2025 for $50,931.59. Total shares outstanding reported are 421,725,450. The filing includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Du Ying, Chairperson & CEO and a director of Zai Lab Ltd (ZLAB), reported insider transactions dated 08/29/2025. The filing shows an acquisition of 604,376 American Depositary Shares (ADSs) at a price of $1.20 per ADS, increasing reported beneficial ownership to 1,141,338 ADSs. The filing also records a disposition of 251,319 ADSs at $32.59 per ADS, leaving 890,019 ADSs reported as beneficially owned after the transactions. The Form 4 discloses that each ADS represents ten ordinary shares and that the stock options underlying the reported acquisition fully vested on March 9, 2021. The form is signed by an attorney-in-fact on behalf of the reporting person on 09/03/2025.
Zai Lab Ltd (ZLAB) insider activity: Joshua L. Smiley, President and Chief Operating Officer, reported vesting of 15,900 Restricted Share Units (RSUs) on 08/15/2025 that resulted in the acquisition of 15,900 American Depositary Shares (ADSs). A subsequent automatic sale on 08/18/2025 disposed of 6,641 ADSs at a price of $36.236 per ADS to cover taxes. After these transactions the filing reports 76,604 ADSs beneficially owned and 31,800 RSU-related derivative securities reported as beneficially owned. The RSUs vest in equal annual installments over five years beginning 08/15/2023.
Insider transactions by Zai Lab Ltd (ZLAB): Chief Legal Officer Edmondson Frazor Titus III reported acquisition and disposition of American Depositary Shares (ADSs) tied to restricted share units (RSUs). On 08/15/2025, 4,850 ADSs were acquired upon vesting of RSUs; each ADS represents ten ordinary shares. The RSUs vest in equal annual installments over five years beginning 08/17/2021. On 08/18/2025, 1,883 ADSs were sold at $36.236 per ADS to cover taxes upon vesting. Following these transactions, the reporting person beneficially owned 42,065 ADSs. The Form 4 was filed individually and signed by an attorney-in-fact.
Chen Yajing, Chief Financial Officer of Zai Lab Ltd (ZLAB), reported changes in her beneficial ownership. On 08/14/2025 she had 1,250 restricted share units vest, converting to 1,250 American Depositary Shares (ADSs). On 08/15/2025 she sold 610 ADSs at $35.267 and 828 ADSs at $35.53; the 610-share sale was to cover taxes and the 828-share sale was executed under a Rule 10b5-1 trading plan adopted March 3, 2025.
After these transactions she beneficially owns 16,720 ADSs (each ADS = 10 ordinary shares). The filing was signed by an attorney-in-fact on 08/18/2025.